Working...
ClinicalTrials.gov
ClinicalTrials.gov Menu

Trabectedin Plus Olaparib in Metastatic or Advanced Sarcomas (TOMAS) (TOMAS)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT02398058
Recruitment Status : Recruiting
First Posted : March 25, 2015
Last Update Posted : August 6, 2019
Sponsor:
Collaborators:
PharmaMar
AstraZeneca
Istituto Di Ricerche Farmacologiche Mario Negri
Information provided by (Responsible Party):
Italian Sarcoma Group

Brief Summary:
This is a Phase 1b, multi-site, open-label, non-randomized clinical trial evaluating the safety, tolerability, and pharmacokinetics of escalating doses of olaparib and trabectedin in patients with unresectable advanced/metastatic sarcomas. Patients will continue to be treated on this combination regimen in the absence of disease progression, intolerable toxicity or patient's decision.

Condition or disease Intervention/treatment Phase
Soft Tissue Sarcoma Bone Tumor Drug: trabectedin Drug: olaparib Phase 1

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 50 participants
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Phase Ib Study on the Combination of Trabectedin and Olaparib in Unresectable Advanced/Metastatic Sarcomas After Failure of Standard Therapies
Actual Study Start Date : July 20, 2014
Estimated Primary Completion Date : February 2020
Estimated Study Completion Date : February 2020

Resource links provided by the National Library of Medicine


Arm Intervention/treatment
Experimental: Trabectedin plus olaparib

All patients will be treated with trabectedin and olaparib in an open-label fashion.

The dosage of the drugs at which each patient is treated depends on the dose level reached at the time of enrollment.

Drug: trabectedin
trabectedin will be administered in a 24-h continuous i.v. infusion every 3 weeks
Other Names:
  • ET-743
  • Yondelis

Drug: olaparib
olaparib will be administered in a continuous daily dose every 12 hours
Other Names:
  • AZD-2281
  • Lynparza




Primary Outcome Measures :
  1. maximum tolerated dose [ Time Frame: from start up to 6 weeks ]
    safety will be evaluated according to Common Terminology Criteria for Adverse Events (CTCAE) v 4.03


Secondary Outcome Measures :
  1. Best Overall Response [ Time Frame: baseline and every 2 cycles (6 weeks +/- 1 week) up to 2 years ]
    best overall response will be defined according to the Response Evaluation Criteria in Solid Tumor version 1.1 (RECIST v 1.1)

  2. Clinical Benefit Rate [ Time Frame: baseline and every 2 cycles (6 weeks +/- 1 week) up to 2 years ]
    Clinical Benefit Rate (CBR): will be defined as the rate of CR (complete response) + PR (partial response) + stable disease lasting at least 12 weeks. CR, PR and stable disease will be defined according to RECIST v 1.1.

  3. Growth Modulation Index [ Time Frame: baseline and every 2 cycles (6 weeks +/- 1 week) up to 2 years ]
    Growth modulation index (GMI) will be calculated as: GMI=TTPn/TTPn−1. TTPn: Time To Progression on the new agent. TTP n−1: Time To Progression on the treatment the patient received just before the new agent was started.

  4. Overall Survival [ Time Frame: baseline and up to 2 years ]
    time from the date of enrollment to date of death or to the date being censored at two years (whichever occurs first).

  5. Duration of Tumor Response [ Time Frame: baseline and every 2 cycles (6 weeks +/- 1 week) up to 2 years ]
    Duration of Objective Response (complete or partial responses) will be measured from the date that a complete or partial response is first documented (whichever occurs first) to date of progression or death due to progressive disease, whichever occurs first.

  6. Progression-Free Survival (PFS) [ Time Frame: baseline and every 2 cycles (6 weeks +/- 1 week) up to 2 years ]
    PFS is defined as the time from the date of enrollment to the date of first documentation of disease progression, or to the death from any cause.

  7. Pharmacokinetic of trabectedin (AUC) [ Time Frame: baseline, days 1-2-3-4-5-8-15 of the first two cycles ]
    The concentration-time data will be used for a preliminary assessment of the effect of combination therapy on the single-dose pharmacokinetics of trabectedin and olaparib. The data will be analyzed by noncompartmental methods. Pharmacokinetic parameters for trabectedin: steady state profile, end of infusion concentration, area under the concentration-time curve (AUC), and, if data permit, terminal phase half-life. For these parameters, the following descriptive statistics will be calculated: mean, standard deviation, coefficient of variation, median, and geometric mean. Any drug-drug interaction will be thoroughly searched. For both trabectedin and olaparib all pharmacokinetic evaluations will be done only for the first 2 cycles.

  8. Pharmacokinetic of olaparib (steady state profile and so maximum concentration, minimal concentration, and AUC will be calculated) [ Time Frame: baseline, day -5 cycle 1, day 1 cycle 2, of the first two cycles ]
    The concentration-time data will be used for a preliminary assessment of the effect of combination therapy on the single-dose pharmacokinetics of trabectedin and olaparib. The data will be analyzed by noncompartmental methods. The following pharmacokinetic parameter values will be obtained for olaparib: steady state profile and so maximum concentration, minimal concentration, and AUC will be calculated. For these parameters, the following descriptive statistics will be calculated: mean, standard deviation, coefficient of variation, median, and geometric mean. Any drug-drug interaction will be thoroughly searched. For both trabectedin and olaparib all pharmacokinetic evaluations will be done only for the first 2 cycles.

  9. safety evaluated according to Common Terminology Criteria for Adverse Events (CTCAE) v 4.03 [ Time Frame: baseline up to 28 days after last dose of study treatment up to 2 years ]
    safety will be evaluated according to Common Terminology Criteria for Adverse Events (CTCAE) v 4.03

  10. Biomarkers (composite outcome) [ Time Frame: baseline, day 1-2-8-15 of each cycle up to 2 years ]
    Several gene assessments (expression, amplification/ deletion, single nucleotide polymorphisms) on DNA-damage response-related markers (including but not limited to BRCA 1-2, ERCC 1-2-5, XRCC 1-2-3, RAD51 and 53BP1, PARP 1-2, P-histone H2AX and others) will be conducted. Statistical analysis will be performed to investigate the association between trial outcomes and polymorphisms of these genes.



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • written informed consent
  • histologically documented and not surgically resectable or metastatic sarcomas which progressed after first or further line treatments for relapsing disease
  • Measurable disease as defined by RECIST v1.1.
  • Eastern Cooperative Oncology Group (ECOG) Performance Status of 0/1. ECOG PS 2 are eligible if depends solely on orthopedic problems
  • Estimated life expectancy of ≥ 4 months
  • Age ≥18 years
  • Adequate organ function: Hemoglobin > 10.0 g/dl; Absolute neutrophil count (ANC) >1,500/mm3; Platelet count >= 100,000/μl; Total bilirubin < 1.5 times the upper limit of normal (ULN); ALT and AST < 2.5 x ULN (< 5 x ULN for patients with liver involvement of their cancer); Alkaline phosphatase < 2.5 x ULN; PT-INR/PTT < 1.5 x ULN; Serum creatinine < 1.5 x ULN or creatinine clearance ≥ 50 ml/min; Albumin > 25 g/l; Creatine phosphokinase (CPK) < 2.5 x ULN

Exclusion Criteria:

  • Involvement in the planning and/or conduct of the study
  • Previous enrolment in the present study
  • Participation in another clinical study with an investigational product during the last month
  • Persistent toxicities (≥CTCAE grade 2) with the exception of alopecia, caused by previous anticancer therapies
  • Dementia or significantly altered mental status
  • Patients with any severe and/or uncontrolled medical conditions
  • HIV infection
  • Active clinically serious infections (> grade 2 NCI-CTCAE version 4.03).
  • Active viral hepatitis (HBV or HCV infection)
  • Symptomatic metastatic brain or meningeal tumors (unless the patient is > 6 months from definitive therapy, does not require corticosteroid treatment, has a negative imaging study within 4 weeks of study entry and is clinically stable with respect to the tumor at the time of study entry).
  • Patients with seizure disorders requiring medication (such as steroids or anti-epileptics)
  • Pregnant or breast-feeding patients. Women of childbearing potential must have a negative pregnancy test performed within 7 days before the start of treatment. Both men and women enrolled in this trial must use adequate barrier birth control measures during the course of the trial and 5 months after last dose of study drug
  • Patients with evidence or history of bleeding diathesis
  • Patients undergoing renal dialysis
  • Patients unable to swallow oral medications
  • Uncontrolled diabetes (fasting glucose > 2 x ULN)
  • Patients receiving chronic, systemic treatment with corticosteroids or another immunosuppressive agent (except corticosteroids with a daily dosage equivalent to prednisone ≤ 20 mg for adrenal insufficiency). Topical or inhaled corticosteroids are permitted
  • Patients with a history of another malignancy within 5 years prior to study entry, except curatively treated non-melanotic skin cancer or in-situ cervical cancer or other solid tumors curatively treated with no evidence of disease for ≥5 years.
  • Anticancer chemotherapy or immunotherapy during the study or within 4 weeks of treatment start
  • Radiotherapy during study or within 3 weeks of start of study drug. (Palliative radiotherapy allowed)
  • Major surgery within 4 weeks of start of study
  • Prior exposure to the study drugs or their analogues
  • Patients with known hypersensitivity to trabectedin, olaparib or to their excipients
  • Patients can receive a stable dose of bisphosphonates for bone metastases before and during the study as long as these were started at least 4 weeks prior to treatment with the study drugs
  • Substance abuse, medical, psychological or social conditions that may interfere with the patient's participation in the study or evaluation of the study results
  • A history of noncompliance to medical regimens or inability or unwillingness to return for scheduled visits
  • Corrected QT interval on the 12-lead ECG (QTc) >470 msec (Bazett Formula)
  • use of strong CYP3A4 inhibitors/inducers
  • Patients with myelodysplastic syndrome/acute myeloid leukemia

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02398058


Contacts
Layout table for location contacts
Contact: Giovanni Grignani, MD +390119933623 giovanni.grignani@ircc.it

Locations
Layout table for location information
Italy
Fondazione del Piemonte per l'Oncologia IRCC Candiolo Recruiting
Candiolo, Torino, Italy, 10060
Contact: Giovanni Grignani, MD    0039-011-9933623    giovanni.grignani@ircc.it   
Contact: Lorenzo D'Ambrosio, MD    0039-011-9933623    lorenzo.dambrosio@ircc.it   
Principal Investigator: Giovanni Grignani, MD         
Sub-Investigator: Lorenzo D'Ambrosio, MD         
Istituti Ortopedici Rizzoli - Unit of Chemotherapy of Muscoloskeletal Tumors Recruiting
Bologna, Italy, 40136
Contact: Stefano Ferrari, MD    +39.051.6366 ext 107    stefano.ferrari@ior.it   
Principal Investigator: Stefano Ferrari, MD         
Istituto Nazionale Tumori - Unit of Medical Oncology Not yet recruiting
Milano, Italy, 20133
Contact: Paolo Casali, MD    +39.02.2390 ext 111    paolo.casali@istitutotumori.mi.it   
Principal Investigator: Paolo Casali, MD         
Sponsors and Collaborators
Italian Sarcoma Group
PharmaMar
AstraZeneca
Istituto Di Ricerche Farmacologiche Mario Negri
Investigators
Layout table for investigator information
Principal Investigator: Giovanni Grignani, MD Italian Sarcoma Group

Publications of Results:
Layout table for additonal information
Responsible Party: Italian Sarcoma Group
ClinicalTrials.gov Identifier: NCT02398058     History of Changes
Other Study ID Numbers: TOMAS
2013-003638-33 ( EudraCT Number )
First Posted: March 25, 2015    Key Record Dates
Last Update Posted: August 6, 2019
Last Verified: February 2019

Keywords provided by Italian Sarcoma Group:
trabectedin
olaparib
sarcoma
bone tumor

Additional relevant MeSH terms:
Layout table for MeSH terms
Sarcoma
Bone Neoplasms
Neoplasms, Connective and Soft Tissue
Neoplasms by Histologic Type
Neoplasms
Neoplasms by Site
Bone Diseases
Musculoskeletal Diseases
Olaparib
Trabectedin
Poly(ADP-ribose) Polymerase Inhibitors
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action
Antineoplastic Agents
Antineoplastic Agents, Alkylating
Alkylating Agents